National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)

Over the past decade, multiple trials, including the precision medicine trial National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH, EAY131, NCT02465060) have sought to determine if treating cancer based on specific genomic alterations is effective, irrespective of the cancer hi...

Descripción completa

Detalles Bibliográficos
Autores principales: Meric-Bernstam, Funda, Ford, James M., O'Dwyer, Peter J., Shapiro, Geoffrey I., McShane, Lisa M., Freidlin, Boris, O'Cearbhaill, Roisin E., George, Suzanne, Glade-Bender, Julia, Lyman, Gary H., Tricoli, James V., Patton, David, Hamilton, Stanley R., Gray, Robert J., Hawkins, Douglas S., Ramineni, Bhanumati, Flaherty, Keith T., Grivas, Petros, Yap, Timothy A., Berlin, Jordan, Doroshow, James H., Harris, Lyndsay N., Moscow, Jeffrey A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Perspectives
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10102840/
https://www.ncbi.nlm.nih.gov/pubmed/36662819
http://dx.doi.org/10.1158/1078-0432.CCR-22-3334

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10102840/
https://www.ncbi.nlm.nih.gov/pubmed/36662819
http://dx.doi.org/10.1158/1078-0432.CCR-22-3334

Ejemplares similares